Praetorian Bio, a preclinical biotechnology company developing the first vaccines directly targeting the bacteria behind cavities and gum disease, today announced the successful closing of its $1 million pre-seed financing round.
The financing will accelerate Praetorian Bio’s vaccine programs, which focus on mucosal, needle-free delivery to address the two most prevalent oral diseases worldwide: dental caries and periodontitis. By shifting dentistry from reactive treatments to proactive prevention, the company is pioneering a new paradigm for oral health.
“This pre-seed funding is a critical milestone that enables us to expand our preclinical work, strengthen our scientific team, and prepare for the clinic,” said Dr. Armando Cuesta, Co-CEO of the company. “We are grateful to our early backers, including some well-known VCs and serial entrepreneurs, for believing in our vision to make oral vaccines a reality for billions of people.”
“The strong investor interest we’ve seen at this stage highlights the scale of the opportunity,” added Dr. Ivo Ploemen, Co-CEO of the company. “Oral diseases affect nearly every human being, yet preventive innovation has lagged far behind other fields. We believe Praetorian is uniquely positioned to change that.”
The investment round attracted participation from leading angels and healthcare investors across the U.S. and Europe, many of whom bring deep expertise in biotech and life sciences. The financing coincides with Praetorian Bio’s upcoming scientific presentations at Dentech 2025 and the World Vaccine Congress Europe 2025, where the company will showcase its latest preclinical data.
